DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Maxalt-Mlt (Rizatriptan Benzoate) - Summary

 
 



MAXALT-MLT SUMMARY

MAXALT Tablets and MAXALT-MLT Orally Disintegrating Tablets contain rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.

MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults.

MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.


See all Maxalt-Mlt indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Maxalt-Mlt (Rizatriptan)

In Vino Veritas: The Link Between Migraine and Wine
Source: Medscape NeurologyHeadlines [2014.11.19]
Andrew Wilner discusses a new study investigating the relationship between wine consumption and migraine headaches.
Medscape Neurology

First-in-class nasal spray demonstrates promise for migraine pain relief
Source: Headache / Migraine News From Medical News Today [2014.11.06]
Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines.

Differences in nerve structure and function may help to explain how migraine headaches occur
Source: Headache / Migraine News From Medical News Today [2014.11.06]
Migraine linked to defective 'insulation' around nerve fibers, suggests study in Plastic and Reconstructive SurgeryA new study shows cellular-level changes in nerve structure and function that...

Seizures and migraines in the brain linked
Source: Headache / Migraine News From Medical News Today [2014.11.04]
Seizures and migraines have always been considered separate physiological events in the brain, but now a team of engineers and neuroscientists looking at the brain from a physics viewpoint discovered...

Migraine
Source: MedicineNet Fibromyalgia Specialty [2014.10.20]
Title: Migraine
Category: Diseases and Conditions
Created: 1/31/2014 12:00:00 AM
Last Editorial Review: 10/20/2014 12:00:00 AM

more news >>

Published Studies Related to Maxalt-Mlt (Rizatriptan)

Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.

A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...

Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...

Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. [2011]
The objectives of this study are to assess the efficacy and safety of frovatriptan, and rizatriptan in the subgroup of women with menstrually related migraine of a multicenter, randomized, double blind, cross-over study. Each patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized sequence: after treating 3 episodes of migraine in not more than 3 months with the first treatment, the patient had to switch to the other treatment...

A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.

more studies >>

Clinical Trials Related to Maxalt-Mlt (Rizatriptan)

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Recruiting]

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents [Recruiting]

Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-Autonomic Symptoms. [Not yet recruiting]
Triptans are first choice drugs in the acute treatment of migraine and cluster headache. However, while in cluster headache the response rate to subcutaneous sumatriptan is 96%, around 30% of patients fail to respond to a particular triptan4. Nonresponse is likely to be due to a variety of factors, including low and inconsistent absorption, inadequate dosing, and variability in individual response5. Timing of administration is also a crucial issue. In fact, an early treatment of the attack, when the pain is still mild, may increase the responders rate by circumventing the development of cutaneous allodynia (expression of central sensitization of pain pathway) during the course of the attack6,7.

Several studies have been performed in an attempt to genetically, psychologically and clinically characterize the triptan responders but failed to provide conclusive results8-10.

Nevertheless, we suggested that the presence of UAs during the migraine attack might predict a good response to triptans1,11. UAs are common in migraine patients. They have been reported in almost one out of two migraineurs (45. 8%) attending a tertiary headache centre and in more than one out of four (26. 9%) in a population-based study1,3. In an open study with sumatriptan 50 mg performed on 72 migraine patients with UAs, we described pain relief in 65. 3% of the patients at 1 h and in 81. 9% at 2 h, while pain-free in 30. 6% at 1 h and in 61. 1% at 2 h11. We hypothesized a large-scale recruitment of peripheral neurovascular 5-HT1B/1D receptors consequent to the activation of the trigeminal-autonomic reflex in such patients. Our hypothesis has received further confirmation by the demonstration of higher levels of calcitonin gene-related peptide, neurokinin A and vasoactive intestinal peptide (the hallmark of the activation of the trigeminal autonomic reflex) in external jugular blood in rizatriptan responders than in non-responders 12.

The investigators therefore postulate that migraineurs with UAs may respond better to rizatriptan than "general" migraine population.

Objectives:

To evaluate the efficacy of rizatriptan 10 mg lyophilized wafer (MLT) compared to placebo in the treatment of acute migraine in patients with unilateral autonomic symptoms (UAs: unilateral lacrimation, eye redness, eyelid oedema, nasal congestion or rhinorrhoea, miosis or ptosis, forehead or facial sweating) during the attack

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine [Recruiting]
This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response? [Recruiting]
Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet.

During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.

more trials >>

Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects

Drug Ineffective (3)Intestinal Ischaemia (2)Vomiting (2)Epilepsy (2)Abdominal Pain (1)Cardiac Tamponade (1)Contusion (1)Sudden Death (1)Abortion Spontaneous (1)Drug Label Confusion (1)more >>


Page last updated: 2014-11-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014